Twitxy Saved

Ryan Cross the Science Boss

@RLCscienceboss

Senior Science Correspondent for @Endpts covering biotech, drug discovery, gene editing, RNA, and more. Formerly at Boston Globe and C&EN. Signal: RyanCross.25
Joined February 2015
848 Following 4.5K Followers 2.4K Posts

Latest posts 5

Ryan Cross the Science Boss @RLCscienceboss
Seawolf launches with $100M to make non-viral gene therapies for obesity, muscle loss and osteoporosis. The startup told me the key to delivering DNA with LNPs was a protein that blocks the cell's natural sequestration of foreign DNA. More in @endpts endpoints.news/seawolf-launch…
endpoints.news Seawolf launches with $100M to make non-viral gene therapies for obesity, muscle loss and osteopo... Seawolf Therapeutics launches from stealth with $100M to deliver gene therapy without a virus, targeting obesity, sarcopenia and osteoporosis.
Ryan Cross the Science Boss @RLCscienceboss
Endpoints News is hiring a "Business of Science" reporter! We're looking for someone with experience covering the biotech industry with business savvy and an ability to make sense of important advances in science and medicine. @endpts linkedin.com/jobs/view/4489…
www.linkedin.com Business of Science Reporter at Endpoints News — United States | LinkedIn Jobs Apply for Business of Science Reporter at Endpoints News in United States. Full-time Entry level role. See responsibilities, qualifications, and similar jobs on LinkedIn.
Ryan Cross the Science Boss @RLCscienceboss
Cancer immunotherapy has struggled to build on its initial success. Big pharma is backing out of the field, and former Genentech leader Ira Mellman is forming a plan to keep the promise of immunotherapy alive at the Parker Institute. My latest for @endpts: endpoints.news/ira-mellman-wa…
endpoints.news Cancer is a ‘wily foe,’ and Ira Mellman fears drugmakers are quitting the immunotherapy fight early Ira Mellman, ex-Genentech, now leads Parker Institute research, pushing cancer immunotherapy over precision drugs like Revolution Medicines' daraxonrasib, calling incremental advances insufficient.